Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Spotify Technology — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Spotify Technology trades at $480.5 (market cap $98.92B). The key difference: Spotify Technology is far larger — about 12.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| BIO | SPOT | |
|---|---|---|
Market Cap | $8.04B | $98.92B |
Sector | Health | Media |
52-Week High | $339.75 | $738.53 |
52-Week Low | $241.71 | $412.75 |
Enterprise Value | $7.85B | $89.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Spotify (SPOT) trades at $479.84, showing minimal daily movement (+0.01%) amid neutral technical signals. The company demonstrates strong fundamental momentum with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability turnaround from losses to $2.2B net income. Recent earnings beats and AI integration initiatives highlight operational strength, though technical indicators show mixed signals with bearish moving averages and neutral oscillators.
Spotify presents a compelling growth story with accelerating profitability and analyst optimism (61.5% buy ratings), though faces execution risks in competitive streaming markets. The stock trades at a premium valuation (P/E 32.7) but offers 28% upside to consensus target of $617. Key risks include market saturation and royalty cost pressures, while AI innovation provides growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
